The Medical Briefing Nephrology
Rituximab and urinary loss, infliximab in interstitial nephritis, low-protein diet, anti-cMET in polycystic kidney disease
Retrospective no. 9/12
The essentials in four articles
■ Glomerular disease
25 patients with primary membranous nephropathy treated with rituximab: urinary rituximab loss correlates with proteinuria and its non-selectivity, with a response rate of 43% vs 100% depending on its extent. Think pharmacokinetics before concluding resistance.
■ Clinical nephrology
75-year-old patient with severe acute interstitial nephritis, corticosteroids stopped for psychosis: two infliximab infusions, hemodialysis stopped, creatinine from 16.5 to 1.6 mg/dL at 9 months. Single case, prospective evaluation needed.
■ CKD and dialysis
Italian study (62 stage 4–5 CKD patients on a low-protein diet with ketoanalogues, 123 controls, 5 years): dialysis-free survival 48.6 vs 28.8 months, overall costs reduced by about 30%.
■ CKD and dialysis
Preclinical: a dimeric IgA antibody directed against cMET reaches the cyst lumen via pIgR; in mice, it slows cyst growth and improves kidney function, with good tolerability.